statistiche ricercatore

Continente	#
EU - Europa	457
AS - Asia	403
NA - Nord America	255
SA - Sud America	45
AF - Africa	4
Continente sconosciuto - Info sul continente non disponibili	1
OC - Oceania	1
Totale	1.166

Nome	#
D898_E901 RET Deletion Is Oncogenic, Responds to Selpercatinib, and Treatment Resistance Can Arise Via RET-Independent Mechanisms	148
Identification of Novel Small Molecule Inhibitors of Oncogenic RET Kinase	140
Mechanisms of RET mediated signal transduction	133
Fragment-Based Discovery of a Dual pan-RET/VEGFR2 Kinase Inhibitor Optimized for Single-Agent Polypharmacology	117
Targeted activity of the small molecule kinase inhibitor Pz-1 towards RET and TRK kinases	116
Bioisosteric discovery of npa101.3, a second-generation ret/vegfr2 inhibitor optimized for single-agent polypharmacology	112
Ret gene fusions in malignancies of the thyroid and other tissues	101
Ultrasound-induced mechanical damage of cancer cell cytoskeleton causes disruption of nuclear envelope and activation of cGAS-STING	91
Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose	86
Discovery of pyrazolo-thieno[3,2-d]pyrimidinylamino-phenyl acetamides as type-II pan-tropomyosin receptor kinase (TRK) inhibitors: Design, synthesis, and biological evaluation	70
Identification of two novel RET kinase inhibitors through MCR-based drug discovery: design, synthesis and evaluation	66
Discovery of N-(3-fluorophenyl)-2-(4-((7-(1-methyl-1H-pyrazol-4-yl)quinazolin-4-yl)amino)phenyl)acetamide as the first orally active selective aurora kinase B inhibitor	15
Totale	1.195

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2020/2021	14	0	0	0	0	0	1	0	1	0	0	9	3
2021/2022	79	2	2	17	0	0	0	2	12	4	8	10	22
2022/2023	71	8	1	1	3	12	9	0	10	12	3	12	0
2023/2024	97	1	17	13	9	9	19	2	9	6	2	8	2
2024/2025	386	25	15	5	5	18	42	47	37	15	38	102	37
2025/2026	471	98	69	93	54	129	28	0	0	0	0	0	0
Totale													1.195